Invitae

The company plans to sell 9 million shares at $19.00 per share, which is expected to bring in $171.0 million in gross proceeds.

Invitae hasn't priced the offering yet or disclosed how many shares it will offer, but it expects net proceeds to range from $117.1 million to $134.7 million.

Many diagnostic firms saw gains in their stock prices last month as Invitae and NantHealth also saw healthy increases.

Free genetic testing on a broad gene panel is available to children, from birth to five years old, if they've had an unprovoked seizure.

For the last three months of 2018, Invitae reported $45.4 million in revenues compared to $25.4 million in Q4 2017, beating the consensus Wall Street estimate.

In an effort to lift patient access barriers, the company is launching a model whereby consumers will be able to initiate test orders online.